14.6 C
New York
Saturday, November 21, 2026

Merck Cancer Drug Extends Survival in Late Trial

Must read

Rajiv
Rajivhttps://trendsnewsstories.com/
Rajiv writes and edits news and explainers for Trends News Stories, based in New Delhi, India.

Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial. The drug, sacituzumab tirumotecan, also known as sac-TMT, met the trial’s main goal of improving overall survival, the company said. The trial enrolled 473 patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments. Merck did not disclose detailed data, which it plans to present at a future medical meeting.

What the Merck trial tested

The study, called TroFuse-015, was a randomized, open-label, multicenter Phase 3 trial in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. It compared sac-TMT with physician’s choice of chemotherapy: trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Patients were assigned at random to sac-TMT or one of the four physician-selected treatments. Sac-TMT is an antibody-drug conjugate, a type of targeted cancer therapy that pairs an antibody that seeks out a protein on cancer cells with a drug that kills them, designed to deliver cancer-killing drugs directly to tumor cells while limiting damage to healthy tissue. The drug targets TROP2, a cell-surface protein found in high amounts in several cancers. Sacituzumab tirumotecan was given at 4 mg/kg on days 1, 15 and 29 of each six-week cycle.

Merck drug missed a second goal

The trial did not meet its secondary goal of delaying cancer progression, as measured by an independent review. The objective response rate nominally favored sac-TMT, but that difference was not formally tested under the prespecified analysis plan. Merck said the drug had no new safety concerns. The company described the overall survival improvement as clinically meaningful. The company said the survival results were generally consistent across subgroups regardless of TROP2 expression status, and that the study was the first global Phase 3 trial to show an overall survival benefit with a TROP2-directed antibody-drug conjugate in this population.

Analysts at RBC Capital Markets wrote in a note on Friday that it is not unusual in cancer trials to see survival improve even when progression-free survival does not, and that overall survival remains the gold standard in these settings. The note followed the company’s announcement, which gave the headline result without the underlying numbers. Neither the company nor its partner shared the data behind the headline result, and the detailed numbers will come when the data are presented at a medical meeting. Overall survival remains the measure doctors watch most closely in these settings. The company has not published median survival by treatment group, a hazard ratio, a confidence interval or a p-value, and those figures will matter when doctors judge how large the benefit is.

Where the Merck program goes next

Merck licensed sac-TMT from China’s Kelun-Biotech for markets outside Greater China. The result is the second Phase 3 success in the company’s TroFuse program, after a trial in endometrial cancer reported an overall survival benefit in October. The program has 18 ongoing Phase 3 studies across tumor types including endometrial, bladder, breast, cervical, gastric, lung and ovarian cancers. Merck said it plans to present the TroFuse-015 data at an upcoming medical meeting and share the findings with regulatory authorities.

The drug is already approved in four indications in China, where Kelun-Biotech discovered it. The company holds exclusive rights to develop, manufacture and sell it outside Greater China. The broader TroFuse program is testing the drug both alone and in combination with immunotherapies, in studies that cover breast, bladder, ovarian and non-small cell lung cancers as well as gastrointestinal tumors.

Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, said sac-TMT was “the first TROP2 ADC to improve OS in a global Phase 3 study in advanced gastroesophageal adenocarcinoma compared to TPC, demonstrating its potential in a particularly challenging disease setting.”

Sac-TMT is under FDA priority review for previously treated endometrial cancer, with a decision expected by June 2027. Merck is currently testing sac-TMT for multiple cancers, including lung, breast and gastrointestinal tumors. The company announced the TroFuse-015 results on November 20, 2026.

More articles

Latest article